Portfolio | 基因编辑公司博雅辑因（EdiGene）宣布完成亿元PRE-B轮融资

中国北京，美国剑桥-（2018年8月8日）- 博雅辑因集团（EdiGene Inc.）宣布完成亿元Pre-B轮融资。本次融资由礼来亚洲基金领投、华盖资本跟投，公司A轮领投方IDG资本、中经合及龚洪嘉等投资人继续跟随投资。

“公司的基因编辑治疗项目潜力巨大，本次融资可为公司基因编辑治疗项目的下一步发展提供充足的资金，” 博雅辑因CEO魏东博士说道，“此外，基于持续积累的技术创新和自主知识产权，我们将开发一系列更为综合全面的高通量遗传筛选方案，满足客户在药物敏感、抗药及合成致死等基因筛选方面的需求。”

“很高兴可以在短期内融到一笔资金，迅速将公司推进至下一阶段。本轮融资，引入了礼来亚洲基金等新的资本，同时也有最了解公司运营状况的原有股东及董事的跟投，这显示出资本市场对公司的兴趣和认可，是对公司近年来工作的肯定，也是对公司未来潜力的笃信。” 博雅辑因创始人魏文胜博士说：“我们非常期待与礼来亚洲基金及其他投资人一起，共同推动公司各产品线向前发展，朝着最终治愈患者更进一步。”

“能够投资博雅辑因，我们感到非常振奋，” 礼来亚洲基金管理合伙人陈飞博士表示：“基因编辑技术让疾病治疗及药物开发有了突破性进展。我们很高兴可以与博雅辑因团队合作，并支持其在全球的发展。”

关于博雅辑因（EdiGene）

博雅辑因（EdiGene Inc.）成立于2015年，目前总部设在北京，并在广州及美国剑桥拥有分公司。博雅辑因致力于将前沿的基因编辑技术转化为治病救人的良方；同时使用创新的高通量遗传筛选技术，产生功能性生物大数据，为新药开发提速。博雅辑因是国家高新技术企业，被生物技术顶级期刊Nature Biotechnology评为2017受资本青睐的技术密集型初创企业。

关于礼来亚洲基金（LAV）

礼来亚洲基金成立于2008年，总部上海，是一家领先的风险投资公司，专注于投资中国及美国的生物医药、制药、医疗器械及诊断行业。礼来亚洲基金不仅为初创及成长型企业提供资金支持，更为企业带来行业经验及宝贵的资源。礼来亚洲基金在加利福尼亚、上海及香港拥有办事处。

更多信息请见 www.edigene.com.

媒体联系人
王萌[e-mail]

附英文新闻：

Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing

August 08, 2018 

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of approximately $15 Million in a Series pre-B financing.

The financing is led by new investor Lilly Asia Ventures (LAV). New investor Huagai Capital participated in this round. Series A lead investor IDG Capital, Series A investor WI Harper Group and other insiders also participated in this round.

“This investment will allow us to continue advancing our promising portfolio of therapeutic programs based on gene-editing technologies,” said Dr. Dong Wei, CEO of EdiGene, “In addition, we will continue to further develop our proprietary High Throughput Genome Screening platforms into a comprehensive solution for our partners in key areas such as drug sensitivity, drug resistance and synthetic lethality.”

“This new round of financing led by Lilly Asia Ventures with participation of new and existing investors further validates the progress we have made and the potential of our platforms,” said Dr. Wensheng Wei, founder of EdiGene. “Now we are well positioned to further advance our pipeline and get one step closer to help patients with our technologies. We look forward to working with Lilly Asia Ventures and other investors for the years to come.”

"We are excited to invest in EdiGene,” said Dr. Fei Chen, Managing Partner of Lilly Asia Ventures, “Gene editing is bringing evolutional breakthrough to drug discovery and potential clinical therapeutics, and we are pleased to collaborate with EdiGene team and to support EdiGene’s growth in the global market.”

About EdiGene, Inc

EdiGene Inc is founded in 2015, and now headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. Our mission is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. We leverage our proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.

About Lilly Asia Ventures (LAV)

Founded in 2008 and headquartered in Shanghai, LAV is a leading VC firm investing in the biomedical, pharmaceutical and medical devices/diagnostics industries in China and US. LAV provides early-to-growth-stage companies with wise capital, professional expertise and valuable resources. LAV has offices in northern California, Shanghai and Hong Kong.

Contact:

EdiGene Inc.

Meng Wang, [phone]

[e-mail]

www.edigene.com

近期文章

Portfolio公司新闻

行业趋势

原创

欢迎关注：